Journal ArticleDOI
Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.
Reads0
Chats0
TLDR
The incidence of thromboembolic complications and vascular mortality were significantly lower in the warfarin group than in the aspirin and placebo groups, which did not differ significantly.About:
This article is published in The Lancet.The article was published on 1989-01-28. It has received 1636 citations till now. The article focuses on the topics: Warfarin & Stroke.read more
Citations
More filters
Journal ArticleDOI
Comparative Effectiveness of Interventions for Stroke Prevention in Atrial Fibrillation: A Network Meta‐Analysis
TL;DR: The entire spectrum of therapy to prevent thromboembolism in nonvalvular AF significantly reduced stroke/systemic embolism events and mortality.
Journal ArticleDOI
Design and Rationale of the RE-DUAL PCI Trial : A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting
Christopher P. Cannon,Christopher P. Cannon,Savion Gropper,Deepak L. Bhatt,Deepak L. Bhatt,Stephen G. Ellis,Takeshi Kimura,Gregory Y.H. Lip,Ph. Gabriel Steg,Ph. Gabriel Steg,Jurriën M. ten Berg,Jenny Manassie,Jörg Kreuzer,Jörg Kreuzer,Jon Blatchford,Joseph M. Massaro,Martina Brueckmann,Martina Brueckmann,Ernesto Ferreiros Ripoll,Jonas Oldgren,Stefan H. Hohnloser +20 more
TL;DR: The RE-DUAL PCI trial (NCT 02164864) is a phase 3b, a strategy of prospective, randomized, open-label, blinded-endpoint trial as mentioned in this paper, where the main objective is to evaluate dual antithrombotic therapy with dabigatran etexilate (110 or 150 mg twice daily) and a P2Y12 inhibtor (either clopidogrel or ticagrelor) in nonvalvular AF patients who have undergone percutaneous coronary intervention with stenting.
Journal ArticleDOI
Primary stroke prevention.
TL;DR: Evidence‐based recommendations for primary stroke prevention are presented and changes to modifiable risk factors, the role of drugs and surgery are discussed, and new markers may help identification of subjects at high risk.
Journal ArticleDOI
Atrial fibrillation, stroke, and anticoagulation in Medicare beneficiaries: trends by age, sex, and race, 1992-2010.
TL;DR: Ischemic stroke rates among Medicare AF patients decreased significantly in all demographic subpopulations from 1992–2010, coincident with increasing warfarin use, and in all age categories, the thromboembolic risk (CHADS) score was significantly higher among women (versus men) and blacks (Versus whites).
Journal ArticleDOI
Guías de actuación clínica de la Sociedad Española de Cardiología. Recomendaciones para el uso del tratamiento antitrombótico en cardiología
Magda Heras,Antonio Fernández Ortiz,José Antonio Gómez Guindal,José A. Iriarte,Rosa-Maria Lidón,Francisco Pérez Gómez,Inmaculada Roldán +6 more
TL;DR: The presente documento es una puesta al dia del documento previo publicado en el ano 1994, una revision exhaustiva de the literatura de los ultimos 15 anos oficiales de cardiologia.
References
More filters
Journal ArticleDOI
A multiple testing procedure for clinical trials.
TL;DR: The overall size of the procedure is shown to be controlled with virtually the same accuracy as the single sample chi-square test based on N(m1 + m2) observations and the power is found to bevirtually the same.
Journal ArticleDOI
Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The Framingham Study
TL;DR: Controlled trials of anticoagulants or antiarrhythmic agents in persons with chronic AF may demonstrate if strokes can be prevented in this highly susceptible group.
Journal ArticleDOI
Explanatory and pragmatic attitudes in therapeutical trials
Daniel Schwartz,Joseph Lellouch +1 more
TL;DR: Most therapeutic trials are inadequately formulated from the earliest stages of their conception, and it often occurs that one type of approach is ethically less defensible than the other, or may even be ruled out altogether on ethical grounds.
Journal ArticleDOI
Randomised trial of prophylactic daily aspirin in British male doctors
Richard Peto,Richard Gray,Rory Collins,Keith Wheatley,Charles H. Hennekens,K Jamrozik,Charles Warlow,B Hafner,E Thompson,S Norton +9 more
TL;DR: A six year randomised trial was conducted among 5139 apparently healthy male doctors to see whether 500 mg aspirin daily would reduce the incidence of and mortality from stroke, myocardial infarction, or other vascular conditions.
Journal ArticleDOI
The natural history of lone atrial fibrillation. A population-based study over three decades.
Stephen L. Kopecky,Bernard J. Gersh,Michael D. McGoon,Jack P. Whisnant,David R. Holmes,Duane M. Ilstrup,Robert L. Frye +6 more
TL;DR: It is concluded that lone atrial fibrillation in patients under the age of 60 at diagnosis is associated with a very low risk of stroke, and routine anticoagulation may not be warranted.
Related Papers (5)
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke
Mg Ceravolo,Leandro Provinciali +1 more